By Mackenzie Tatananni

DexCom stock was on the rise Thursday after the maker of medical technology said it had received clearance from the U.S. Food and Drug Administration for a new glucose monitoring system.

Shares of the medical device manufacturer, which specializes in systems for diabetes patients, climbed 2.9% on Thursday. The gains came after DexCom said its G7 15 Day system had been cleared for use in the U.S. for people age 18 years and older.

The device is known as a continuous glucose monitor, so-called because it frequently measures the amount of sugar in someone's blood, as opposed to traditional techniques that require patients to prick their finger for a blood sample at specified times.

Patients can wear the system for up to 15.5 days before it must be replaced, DexCom said. The device is a successor to the DexCom G7, which first became available for purchase at the start of 2023.

"This milestone sets a new standard in CGM and is a testament to our continued leadership in glucose biosensing," CEO Jake Leach said in a statement. He indicated that the new product would hit the market in the second half of 2025.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

April 10, 2025 11:34 ET (15:34 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.